# HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

> **NCT01387932** · PHASE3 · TERMINATED · sponsor: **Merit Medical Systems, Inc.** · enrollment: 235 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** HepaSphere/QuadraSphere Microspheres
- **PROCEDURE:** PVA, lipiodol, doxorubicin

## Key facts

- **NCT ID:** NCT01387932
- **Lead sponsor:** Merit Medical Systems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2021-02
- **Final completion:** 2021-02
- **Target enrollment:** 235 (ACTUAL)
- **Why stopped:** The clinical study was terminated due to the inability to meet target enrollment.
- **Last updated:** 2021-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01387932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01387932, "HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01387932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*